# Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

> **NCT04299191** · PHASE1,PHASE2 · RECRUITING · sponsor: **Laminar Pharmaceuticals** · enrollment: 28 (estimated)

## Conditions studied

- High-grade Glioma
- Solid Tumor, Unspecified, Child

## Interventions

- **DRUG:** LAM561

## Key facts

- **NCT ID:** NCT04299191
- **Lead sponsor:** Laminar Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-01
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04299191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04299191, "Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04299191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*